Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) ...

Key Points Moderna has struggled since COVID-19 vaccine demand has shrunk.The stock has correspondingly declined, as revenue has nosedived over the last few years.The long game is clinical trials in ...

Moderna will offer free COVID-19 vaccines for "uninsured or underinsured people," the company announced Wednesday, pledging to ensure continued access to the shots after the public health ...

Moderna Chief Medical Officer Dr. Paul Burton said he believes the company's "highly effective" updated COVID-19 bivalent vaccine could be a pandemic "turning point." ...